Appropriate and inappropriate use of dronedarone in 2013

Current Treatment Options in Cardiovascular Medicine

Volumn 15, Issue 4, 2013, Pages 467-475

  Naccarelli, Gerald V ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

ANDROMEDA trial; Appropriate vs inappropriate; ATHENA trial; Atrial fibrillation; Dronedarone

Indexed keywords

AMIODARONE; DIGOXIN; DRONEDARONE; PLACEBO; RANOLAZINE;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART ATRIUM PACEMAKER; HEART DEATH; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; INTERSTITIAL LUNG DISEASE; LIVER CELL DAMAGE; LIVER DISEASE; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG DISEASE; LUNG TOXICITY; NAUSEA; OUTCOME ASSESSMENT; PNEUMONIA; QT PROLONGATION; RISK REDUCTION; SIDE EFFECT; SINUS RHYTHM; THYROID DISEASE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

EID: 84881061014     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-013-0246-5     Document Type: Article

References (16)

1. Naccarelli GV, Wolbrette DL, Levin V, Samii S, Banchs JE, Penny-Peterson E, et al. Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter. Clin Med Insights. 2011;5:103-19. Thorough review of the safety, pharmacology, and efficacy of dronedarone.
2. Touboul P, Brugada J, Capucci A, Crÿns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24:1481-7.
3. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-99.
4. Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the efficacy and safety of dronedarone for the control of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156:527-9.
5. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-87.
6. Hohnloser SH, Crijns HJGM, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-78.
7. Connolly SJ, Crijns HJGM, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL, et al. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009;120:1174-80.
8. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone vs amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597-605. Comparative study demonstrating that amiodrone was more effective but dronedarone had less adverse events.
9. Ezekowitz M, Di Marco J, Kaszala K, Ellenbogen K, Boddy A. HESTIA (the effects of dronedarone on atrial fibrillation burden in subjects with permanent pacemakers) Circulation. 2012;126:A15020(abstract). Pacemaker study demonstrating that dronedarone reduced AF burden.
10. Burashnikov A, Belardinelli L, Antzelevitch C. Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria. Heart Rhythm. 2010;7(9):1273-9. J Am Coll Cardiol 2010;56:1216-24. Basic study suggesting that dronedarone has less efficacy in suppressing AF than amiodarone.
11. Burashnikov A, Sicour S, Di Diego JM, Belardinelli L, Antzelevitch C. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol. 2010;56:1216-24. Basic study suggesting that the combination of dronedarone and ranolazine have a synergistic effect in suppressing AF.
12. ClinicalTrials.gov - NCT01522651. Clinical trials description of HARMONY.
13. Connolly SJ, Camm AJ, Halperin JL, for the PALLAS Investigators, et al. Dronedarone in high risk permanent atrial fibrillation. N Engl J Med. 2011;365:2268-76. PALLAS demonstrated a worsening of cardiovascular outcomes with dronedarone in permanent AF/AFl.
14. Joghetaei N, Weirich G, Huber W, Buchler P, Estner H. Acute liver failure with dronedarone. Circ Arrhythm Electrophysiol. 2011;4:592-3. Review of case reports of severe hepatic toxicity possibly secondary to dronedarone.
15. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:104-23. Focused USA guideline on the use of dronedarone.
16. Camm AJ, Lip GY, De Caterina R, Savilieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33(21):2719-47. Most recent European guideline reviewing dronedarone's role after PALLAS.